|
20 Jan 2022 |
Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors
|
|
19 Jan 2022 |
ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
|
|
19 Jan 2022 |
Altos Labs launches with the goal to transform medicine through cellular rejuvenation programming
|
|
19 Jan 2022 |
FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC
|
|
19 Jan 2022 |
CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients
|
|
19 Jan 2022 |
Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)
|
|
19 Jan 2022 |
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III
|
|
19 Jan 2022 |
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
|
|
19 Jan 2022 |
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
|
|
19 Jan 2022 |
Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer
|
|
19 Jan 2022 |
Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive at three years
|
|
19 Jan 2022 |
First subject enrolled in phase II/III study of Eisai's anti-MTBR tau antibody E2814 for dominantly inherited Alzheimer's disease (DIAD), conducted by DIAN-TU
|
|
19 Jan 2022 |
UCB to acquire Zogenix
|
|
18 Jan 2022 |
23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program
|
|
18 Jan 2022 |
Akeso's AK117 (CD47 monoclonal antibody) in Combination with AK112 (PD-1/VEGF bi-specific antibody) to Initiate a Phase Ib/II Clinical Trial with or without Chemotherapy for the Treatment of Advanced Malignant Tumors
|
|
18 Jan 2022 |
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
|
|
18 Jan 2022 |
Amagma Therapeutics Announces Strategic Partnership with Innovent Biologics in Inflammatory Diseases
|
|
18 Jan 2022 |
City of Hope and CytoImmune announce study demonstrating novel off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell-based therapy against pancreatic cancer
|
|
18 Jan 2022 |
Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
|
|
18 Jan 2022 |
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy
|
